clonazepam has been researched along with Opsoclonus-Myoclonus Syndrome in 9 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Opsoclonus-Myoclonus Syndrome: A neurological condition that is characterized by uncontrolled rapid irregular movements of the eye (OPSOCLONUS) and the muscle (MYOCLONUS) causing unsteady, trembling gait. It is also known as dancing eyes-dancing feet syndrome and is often associated with neoplasms, viral infections, or autoimmune disorders involving the nervous system.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since the emergence of coronavirus disease 2019 (COVID-19), neurological symptoms, syndromes, and complications associated with this multi-organ viral infection have been reported and the various aspects of neurological involvement are increasingly uncovered." | 2.72 | Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. ( Aghavali, S; Babadi, M; Daraie, P; Emamikhah, M; Jalili, M; Mehrabani, M; Mohaghegh, F; Pouranian, M; Rohani, M; Zaribafian, M, 2021) |
| "We present a child with paraneoplastic opsoclonus myoclonus syndrome who responded well to clonazepam." | 1.36 | Clonazepam responsive opsoclonus myoclonus syndrome: additional evidence in favour of fastigial nucleus disinhibition hypothesis? ( Chandra, S; Kalita, J; Misra, UK; Paliwal, VK; Verma, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Nelson, JL | 1 |
| Blume, GM | 1 |
| Bansal, SK | 1 |
| Kaufman, JR | 1 |
| Woods, FR | 1 |
| Zhang, X | 1 |
| Kattah, JC | 1 |
| Chen, Y | 1 |
| Chen, D | 1 |
| Zhou, X | 1 |
| Zhang, H | 1 |
| Liao, S | 1 |
| Xu, Z | 1 |
| Xu, P | 1 |
| Emamikhah, M | 1 |
| Babadi, M | 1 |
| Mehrabani, M | 1 |
| Jalili, M | 1 |
| Pouranian, M | 1 |
| Daraie, P | 1 |
| Mohaghegh, F | 1 |
| Aghavali, S | 1 |
| Zaribafian, M | 1 |
| Rohani, M | 1 |
| Urrea-Mendoza, E | 1 |
| Okafor, K | 1 |
| Ravindran, S | 1 |
| Absher, J | 1 |
| Chaubal, V | 1 |
| Revilla, FJ | 1 |
| Koziorowska-Gawron, E | 1 |
| Koszewicz, M | 1 |
| Bladowska, J | 1 |
| Ejma, M | 1 |
| Budrewicz, S | 1 |
| Miyoshi, H | 1 |
| Nakamura, R | 1 |
| Yamaga, A | 1 |
| Haraki, T | 1 |
| Yasuda, T | 1 |
| Hamada, H | 1 |
| Kawamoto, M | 1 |
| Paliwal, VK | 1 |
| Chandra, S | 1 |
| Verma, R | 1 |
| Kalita, J | 1 |
| Misra, UK | 1 |
| Ertekin, V | 1 |
| Tan, H | 1 |
| Bartos, A | 1 |
1 review available for clonazepam and Opsoclonus-Myoclonus Syndrome
| Article | Year |
|---|---|
Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.
Topics: Adult; Anticonvulsants; Ataxia; Azithromycin; Clonazepam; Cough; COVID-19; COVID-19 Drug Treatment; | 2021 |
8 other studies available for clonazepam and Opsoclonus-Myoclonus Syndrome
| Article | Year |
|---|---|
Postinfectious SARS-CoV-2 Opsoclonus-Myoclonus-Ataxia Syndrome.
Topics: Cerebellar Ataxia; Clonazepam; COVID-19; Female; Humans; Immunoglobulin G; Methylprednisolone Hemisu | 2022 |
Opsoclonus-myoclonus syndrome associated with herpes simplex virus infection: a case report.
Topics: Clonazepam; Female; Herpes Simplex; Humans; Methylprednisolone; Middle Aged; Opsoclonus-Myoclonus Sy | 2021 |
Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) Associated with SARS-CoV-2 Infection: Post-Infectious Neurological Complication with Benign Prognosis.
Topics: Adult; Clonazepam; COVID-19; GABA Agents; Humans; Male; Methylprednisolone; Neuroprotective Agents; | 2021 |
Opsoclonus-myoclonus syndrome with severe clinical course and beneficial outcome: A case report.
Topics: Adult; Anticonvulsants; Clonazepam; Female; Glucocorticoids; Humans; Methylprednisolone; Opsoclonus- | 2021 |
Transient symptomatic worsening by atropine in opsoclonus-myoclonus syndrome.
Topics: Adjuvants, Anesthesia; Anticonvulsants; Atropine; Child, Preschool; Clonazepam; Deep Sedation; Drug | 2017 |
Clonazepam responsive opsoclonus myoclonus syndrome: additional evidence in favour of fastigial nucleus disinhibition hypothesis?
Topics: Autoantibodies; Cerebellar Cortex; Cerebellar Nuclei; Clonazepam; Efferent Pathways; GABA Modulators | 2010 |
Opsoclonus-myoclonus syndrome attributable to hepatitis C infection.
Topics: Child; Clonazepam; GABA Modulators; Hepatitis C; Humans; Male; Opsoclonus-Myoclonus Syndrome; Treatm | 2010 |
Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis.
Topics: Adult; Anticonvulsants; Brain; Clonazepam; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid | 2006 |